Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Hepatitis C in Australia - a role for general practitioners?

Baker D, McMurchie M, Farr V.

Med J Aust. 2018 Mar 5;208(4):190. No abstract available.

PMID:
29490227
2.

The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.

Beyrer C, Birx DL, Bekker LG, Barré-Sinoussi F, Cahn P, Dybul MR, Eholié SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibé M, Montaner JS; Vancouver Consensus Signatories.

Lancet. 2015 Aug 8;386(9993):505-7. doi: 10.1016/S0140-6736(15)61458-1. No abstract available.

PMID:
26293427
3.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

4.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

5.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

6.

Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.

Bloch M, Tong WW, Hoy J, Baker D, Lee FJ, Richardson R, Carr A; TROP (Switch from Tenofovir to Raltegravir for Low Bone Density) study team.

HIV Med. 2014 Jul;15(6):373-80. doi: 10.1111/hiv.12123. Epub 2014 Jan 26.

7.

Surviving an epidemic -- Australian GPs on caring for people with HIV and AIDS in the early years.

Newman CE, Reynolds R, Gray R, Canavan P, De Wit J, McMurchie M, McCoy R, Kidd MR.

Aust Fam Physician. 2013 Oct;42(10):734-8.

8.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

9.

Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.

Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA; ADCC study collaboration investigators, Stratov I, Navis M, Kent SJ.

Immunology. 2013 Feb;138(2):116-23. doi: 10.1111/imm.12016.

10.

Platelet count kinetics following interruption of antiretroviral treatment.

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group.

AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d.

11.

HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcome.

Ammaranond P, van Bockel DJ, Petoumenos K, McMurchie M, Finlayson R, Middleton MG, Davenport MP, Venturi V, Suzuki K, Gelgor L, Kaldor JM, Cooper DA, Kelleher AD.

J Immunol. 2011 Jan 1;186(1):479-88. doi: 10.4049/jimmunol.0903227. Epub 2010 Nov 29.

12.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

13.

Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.

Carey D, Baker D, Petoumenos K, Chuah J, Rogers GD, Watson J, Cooper DA, Emery S, Carr A; FLASH Investigators.

HIV Med. 2009 Mar;10(3):163-72. doi: 10.1111/j.1468-1293.2008.00667.x.

14.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

15.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

16.

2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study.

Bodsworth N, Bloch M, McNulty A, Denham I, Doong N, Trottier S, Adena M, Bonney MA, Agnew J; Australo-Canadian FaST Famciclovir Short-Course Herpes Therapy Study Group.

Sex Health. 2008 Sep;5(3):219-25. Erratum in: Sex Health. 2008 Dec;5(4):379.

PMID:
18771636
17.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

PMID:
18476293
18.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
19.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group.

Lancet. 2007 Jul 7;370(9581):49-58.

PMID:
17617272
20.

Supplemental Content

Loading ...
Support Center